ArticleThe Yale journal of biology and medicine2025
Ketoconazole for Cutaneous Leishmaniasis in the Context of Drug Shortages: A Case Report from Madre de Dios, Peru.
Article in The Yale journal of biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous leishmaniasis (CL) is a neglected tropical disease endemic in the Peruvian Amazon. First-line treatment with pentavalent antimonials was unavailable in Madre de Dios, Peru in early 2024 due to a supply-chain crisis. Oral ketoconazole has shown Case Presentation: A 41-year-old woman (body mass index 48 kg/m²) from a rural community in Madre de Dios presented with two ulcerative lesions (0.8 cm and 1.2 cm) on the dorsal aspect of the left little finger, of 4 weeks' duration. CL was confirmed by Giemsa smear and PCR as Conclusions: In this single-patient experience, oral ketoconazole (200 mg every 12 hours for 6 weeks) appeared to be an effective and well-tolerated alternative for CL during an antimonial shortage. Given the possibility of spontaneous healing in CL and the lack of a control group, controlled clinical trials are warranted before broader adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.